Skip to main content

$0.026 (0.00%)

High

$0.03

Low

$0.03

Trades

35

Turnover

$84,085

Volume

3,174,615
30 June 2023 at 3:42pm
Register to track BIT and receive email alerts.

Completion of Phase 2 HIV-1 Clinical Trials

StockBot

416,823 posts

BIT released this announcement to the ASX on 9 March 2023, 9:59. The announcement is marked as price sensitive, and is 2 page(s) in length and 403.58kb in size.

You can view all announcements from BIT and see how they appear on a price chart on the announcements page.

At the date of this announcement, BIT was 0.000% short sold according to ASIC data. It was ranked the 647th most shorted stock on the ASX. It is now ranked as the 497th most shorted stock on the ASX with 0.028% of total shares short sold as of the latest reported data (20 November 2025).

Other Recent Announcements from BIT
Second Site Approved for Phase 2 Covid-19 Trial 12 May 2023, 10:16
Commencement Phase 2 Covid-19 Clinical Trial 4 May 2023, 9:15
Quarterly Activities/Appendix 4C Cash Flow Report 27 April 2023, 11:00
Completion of Phase 2 HIV-1 Clinical Trials 9 March 2023, 9:59
International Presentation of BIT225 COVID-19 Data 21 February 2023, 10:08
Half Yearly Report and Accounts 17 February 2023, 12:50
Notification of cessation of securities - BIT 1 February 2023, 17:35
You must login or register to post a comment.

You must be logged in to post a reply.

Register to track BIT and receive email alerts.